Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16084066 | 0.91 | PKLR (1.00) | PKLR | |
| SCHEMBL15689514 | 0.85 | PKLR (0.81) | PKLR | |
| SCHEMBL15713683 | 0.84 | PKLR (0.67) | PKLR | |
| SCHEMBL15713381 | 0.83 | PKLR (0.84) | PKLR | |
| SCHEMBL15713347 | 0.82 | PKLR (0.83) | PKLR | |
| SCHEMBL15713345 | 0.80 | PKLR (0.69) | PKLR | |
| SCHEMBL15713691 | 0.79 | PKLR (0.64) | PKLR | |
| SCHEMBL9936551 | 0.79 | PKLR (1.00) | PKLR | |
| SCHEMBL15713606 | 0.79 | PKLR (0.81) | PKLR | |
| SCHEMBL15713692 | 0.79 | PKLR (0.84) | PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104822672-B | The purposes of therapeutic compound and composition as well as PKM2 conditioning agents | 安吉奥斯医药品有限公司 | 2018-08-28 | — | — | CN | disclosed |
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2015-10-29 | — | — | US | disclosed |
| CN-104822672-A | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS INC | 2015-08-05 | — | — | CN | disclosed |
| WO-2014074848-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | PDK1, PDK2, PDK3 | PKLR 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.